Meenakshi Anurag
Cited by
Cited by
Integrated proteogenomic characterization of clear cell renal cell carcinoma
DJ Clark, SM Dhanasekaran, F Petralia, J Pan, X Song, Y Hu, ...
Cell 179 (4), 964-983. e31, 2019
Proteogenomic characterization of endometrial carcinoma
Y Dou, EA Kawaler, DC Zhou, MA Gritsenko, C Huang, L Blumenberg, ...
Cell 180 (4), 729-748. e26, 2020
Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy
K Krug, EJ Jaehnig, S Satpathy, L Blumenberg, A Karpova, M Anurag, ...
Cell 183 (5), 1436-1456. e31, 2020
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma
C Huang, L Chen, SR Savage, RV Eguez, Y Dou, Y Li, ...
Cancer cell 39 (3), 361-379. e16, 2021
A proteogenomic portrait of lung squamous cell carcinoma
S Satpathy, K Krug, PMJ Beltran, SR Savage, F Petralia, C Kumar-Sinha, ...
Cell 184 (16), 4348-4371. e40, 2021
The prognostic effects of somatic mutations in ER-positive breast cancer
OL Griffith, NC Spies, M Anurag, M Griffith, J Luo, D Tu, B Yeo, J Kunisaki, ...
Nature communications 9 (1), 3476, 2018
Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer
JT Lei, J Shao, J Zhang, M Iglesia, DW Chan, J Cao, M Anurag, P Singh, ...
Cell reports 24 (6), 1434-1444. e7, 2018
Microscaled proteogenomic methods for precision oncology
S Satpathy, EJ Jaehnig, K Krug, BJ Kim, AB Saltzman, DW Chan, ...
Nature communications 11 (1), 532, 2020
Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers
M Anurag, N Punturi, J Hoog, MN Bainbridge, MJ Ellis, S Haricharan
Clinical Cancer Research 24 (19), 4887-4899, 2018
Loss of MutL Disrupts Chk2-dependent Cell Cycle Control Through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Cancer Discovery, 2017
Endocrine therapy resistance: new insights
JT Lei, M Anurag, S Haricharan, X Gou, MJ Ellis
The Breast 48, S26-S30, 2019
Immune checkpoint profiles in luminal B breast cancer (Alliance)
M Anurag, M Zhu, C Huang, S Vasaikar, J Wang, J Hoog, S Burugu, ...
JNCI: Journal of the National Cancer Institute 112 (7), 737-746, 2020
Neurofibromin is an estrogen receptor-α transcriptional co-repressor in breast cancer
ZY Zheng, M Anurag, JT Lei, J Cao, P Singh, J Peng, H Kennedy, ...
Cancer cell 37 (3), 387-402. e7, 2020
Integrated proteogenomic characterization of clear cell renal cell carcinoma
DJ Clark, SM Dhanasekaran, F Petralia, J Pan, X Song, Y Hu, ...
Cell 180 (1), 207, 2020
Crowd Sourcing a New Paradigm for Interactome Driven Drug Target Identification in Mycobacterium tuberculosis
R Vashisht, AK Mondal, A Jain, A Shah, P Vishnoi, P Priyadarshini, ...
PloS one 7 (7), e39808, 2012
Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort
AS Cheng, SCY Leung, D Gao, S Burugu, M Anurag, MJ Ellis, TO Nielsen
Breast cancer research and treatment 179, 3-10, 2020
DNA damage repair defects as a new class of endocrine treatment resistance driver
M Anurag, MJ Ellis, S Haricharan
Oncotarget 9 (91), 36252, 2018
Unraveling the potential of intrinsically disordered proteins as drug targets: application to Mycobacterium tuberculosis
M Anurag, D Dash
Molecular BioSystems 5 (12), 1752-1757, 2009
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness
Y Li, TSM Lih, SM Dhanasekaran, R Mannan, L Chen, M Cieslik, Y Wu, ...
Cancer cell 41 (1), 139-163. e17, 2023
A web server for predicting inhibitors against bacterial target GlmU protein
D Singla, M Anurag, D Dash, GPS Raghava
BMC pharmacology 11 (1), 1-9, 2011
The system can't perform the operation now. Try again later.
Articles 1–20